Andreas Goebel1. 1. Pain Research Institute, 3rd Floor, Clinical Sciences Centre, Liverpool University, Liverpool, UK. andreasgoebel@rocketmail.com
Abstract
INTRODUCTION: Over the last 15 years, clinical and experimental data have emerged that suggest that peripheral and central, glial-mediated neuroimmune activation is both necessary and sufficient to sustain chronic pain. Immune modulation appears to be, therefore, a possible new therapeutic option. MATERIALS AND METHODS: The Medline database and international trial registry databases were searched using the keywords "intravenous immunoglobulin" or "IVIG," "pain" or "chronic pain," "neuropathic pain," "CRPS," "complex regional pain syndrome" or "fibromyalgia." RESULTS: Evidence from RCTs suggest that IVIG is effective to reduce pain in complex regional pain syndrome (low-dose IVIG) and post-polio syndrome (high-dose IVIG), and open trials have suggested efficacy in additional pain conditions. CONCLUSION: IVIG therapy may emerge as a novel treatment modality for refractory cases. However, before this drug can be confidently used by clinicians, important questions need to be answered concerning optimal treatment doses, duration of treatment, and its effect on function and quality of life.
INTRODUCTION: Over the last 15 years, clinical and experimental data have emerged that suggest that peripheral and central, glial-mediated neuroimmune activation is both necessary and sufficient to sustain chronic pain. Immune modulation appears to be, therefore, a possible new therapeutic option. MATERIALS AND METHODS: The Medline database and international trial registry databases were searched using the keywords "intravenous immunoglobulin" or "IVIG," "pain" or "chronic pain," "neuropathic pain," "CRPS," "complex regional pain syndrome" or "fibromyalgia." RESULTS: Evidence from RCTs suggest that IVIG is effective to reduce pain in complex regional pain syndrome (low-dose IVIG) and post-polio syndrome (high-dose IVIG), and open trials have suggested efficacy in additional pain conditions. CONCLUSION: IVIG therapy may emerge as a novel treatment modality for refractory cases. However, before this drug can be confidently used by clinicians, important questions need to be answered concerning optimal treatment doses, duration of treatment, and its effect on function and quality of life.
Authors: Irmgard Tegeder; Michael Costigan; Robert S Griffin; Andrea Abele; Inna Belfer; Helmut Schmidt; Corina Ehnert; Jemiel Nejim; Claudiu Marian; Joachim Scholz; Tianxia Wu; Andrew Allchorne; Luda Diatchenko; Alexander M Binshtok; David Goldman; Jan Adolph; Swetha Sama; Steven J Atlas; William A Carlezon; Aram Parsegian; Jörn Lötsch; Roger B Fillingim; William Maixner; Gerd Geisslinger; Mitchell B Max; Clifford J Woolf Journal: Nat Med Date: 2006-10-22 Impact factor: 53.440
Authors: Bianca T A de Greef; Margot Geerts; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies Journal: Trials Date: 2016-07-20 Impact factor: 2.279
Authors: Margot Geerts; Bianca T A de Greef; Maurice Sopacua; Sander M J van Kuijk; Janneke G J Hoeijmakers; Catharina G Faber; Ingemar S J Merkies Journal: Neurology Date: 2021-03-25 Impact factor: 9.910